CL2023000823A1 - Métodos para tratar trastornos asociados a la vía del receptor de melanocortina 4 - Google Patents

Métodos para tratar trastornos asociados a la vía del receptor de melanocortina 4

Info

Publication number
CL2023000823A1
CL2023000823A1 CL2023000823A CL2023000823A CL2023000823A1 CL 2023000823 A1 CL2023000823 A1 CL 2023000823A1 CL 2023000823 A CL2023000823 A CL 2023000823A CL 2023000823 A CL2023000823 A CL 2023000823A CL 2023000823 A1 CL2023000823 A1 CL 2023000823A1
Authority
CL
Chile
Prior art keywords
melanocortin
methods
disorders associated
treat disorders
receptor pathway
Prior art date
Application number
CL2023000823A
Other languages
English (en)
Spanish (es)
Inventor
H T Van Der Ploeg Leonardus
Garfield Alastair
P Shah Bhavik
Original Assignee
Rhythm Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhythm Pharmaceuticals Inc filed Critical Rhythm Pharmaceuticals Inc
Publication of CL2023000823A1 publication Critical patent/CL2023000823A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
CL2023000823A 2020-09-24 2023-03-22 Métodos para tratar trastornos asociados a la vía del receptor de melanocortina 4 CL2023000823A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063082867P 2020-09-24 2020-09-24

Publications (1)

Publication Number Publication Date
CL2023000823A1 true CL2023000823A1 (es) 2023-09-15

Family

ID=80845850

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000823A CL2023000823A1 (es) 2020-09-24 2023-03-22 Métodos para tratar trastornos asociados a la vía del receptor de melanocortina 4

Country Status (13)

Country Link
US (1) US20240058414A1 (https=)
EP (1) EP4216979A4 (https=)
JP (1) JP2023542985A (https=)
KR (1) KR20230095956A (https=)
CN (1) CN116507353A (https=)
AR (1) AR123603A1 (https=)
AU (1) AU2021350017A1 (https=)
CA (1) CA3192873A1 (https=)
CL (1) CL2023000823A1 (https=)
CO (1) CO2022009561A2 (https=)
MX (1) MX2023003360A (https=)
TW (1) TW202228760A (https=)
WO (1) WO2022067086A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023308310A1 (en) * 2022-07-12 2025-01-16 Rhythm Pharmaceuticals, Inc. Methods for treating obesity with an mc4r agonist
EP4618952A2 (en) * 2022-11-18 2025-09-24 Rhythm Pharmaceuticals, Inc. Methods for treating obesity with an mc4r agonist
WO2025106751A1 (en) * 2023-11-14 2025-05-22 Rhythm Pharmaceuticals, Inc. Combinations of a potassium channel activator and an mc4r agonist and related methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2286825T3 (pl) * 2005-07-08 2017-06-30 Ipsen Pharma Ligandy receptora melanokortyny
RU2020120797A (ru) * 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
MA43040A (fr) * 2015-09-30 2018-08-08 Univ Berlin Charite Méthode de traitement de troubles associés à la voie du récepteur de la mélanocortine 4

Also Published As

Publication number Publication date
AU2021350017A1 (en) 2023-05-04
JP2023542985A (ja) 2023-10-12
AU2021350017A9 (en) 2024-10-03
MX2023003360A (es) 2023-06-23
US20240058414A1 (en) 2024-02-22
EP4216979A1 (en) 2023-08-02
WO2022067086A1 (en) 2022-03-31
CN116507353A (zh) 2023-07-28
EP4216979A4 (en) 2024-11-06
AR123603A1 (es) 2022-12-21
CO2022009561A2 (es) 2022-07-19
CA3192873A1 (en) 2022-03-31
KR20230095956A (ko) 2023-06-29
TW202228760A (zh) 2022-08-01

Similar Documents

Publication Publication Date Title
CL2023000823A1 (es) Métodos para tratar trastornos asociados a la vía del receptor de melanocortina 4
CL2022001256A1 (es) Métodos y composiciones para tratar un trastorno asociado con el angiotensinogeno agt
Gressier et al. 5-HTTLPR and gender differences in affective disorders: a systematic review
SA522432294B1 (ar) نظام وعملية للتكسير بالبخار ومعالجة زيت وقود الانحلال الحراري تتضمن الهدرجة الانتقائية والتكسير بالهيدروجين انتقائياً
SA522432291B1 (ar) نظام وعملية للتكسير بالبخار ومعالجة زيت وقود الانحلال الحراري تتضمن الهدرجة الانتقائية والتكسير بالهيدروجين وإعادة تشكيل النفثا
CO2021008998A2 (es) Amidas de pirrolidina iii sustituidas
ZA201903091B (en) Methods of treating inflammatory conditions
PH12022551646A1 (en) Methods for treating pemphigus disorders
MX2016015126A (es) Composiciones de angiotensinogeno (agt) arni y metodos de uso de las mismas.
GT201600227A (es) Vectores de aav para la terapia génica de la retina y el snc
EP4360704A3 (en) Method of treating melanocortin-4 receptor pathway-associated disorders
ES3060591T3 (en) Modified polymerases for improved incorporation of nucleotide analogues
UY32449A (es) Benzazepinas fusionadas como ligandos de receptor de acetilcolina nicotínico neuronal
PH12017502120A1 (en) A method and an apparatus for forming a lignin fraction, a lignin composition and its use
CL2020001936A1 (es) Métodos para el tratamiento de la atrofía muscular espinal.
ECSP23076906A (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
CO2024007225A2 (es) Tratamiento de trastornos hepáticos con un agonista del thr-β
BR112022015015A2 (pt) Usos terapêuticos de tirzepatida
CU20200038A7 (es) Compuestos derivados de pirazolo-pirrolo-pirimidina-diona como inhibidores de p2x3
MX2025004103A (es) Metodos de identificacion de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa
DOP2011000209A (es) Compuestos de quinazolina sustituidos
MX2017011885A (es) Uso de antagonistas de receptores de glucocorticoides en combinacion con glucocorticoides para tratar la insuficiencia adrenal.
MX2023005408A (es) Compuestos y su uso en el tratamiento de trastornos mediados por el receptor de taquiquinina.
UY40350A (es) Métodos para el tratamiento de la obesidad con un agonista mc4r
CL2025002297A1 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa.